A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
Launched by ABBVIE · Oct 20, 2021
Trial Information
Current as of May 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a medication called upadacitinib for treating adults with axial spondyloarthritis (axSpA), a condition that causes chronic back pain and can significantly affect daily life. The trial aims to understand how well this treatment works in real-world settings, including how it helps control pain and improve overall health and well-being for those living with this disease. The study will involve about 352 adults in Germany, and it will last about 52 weeks.
To participate, individuals must have a doctor’s diagnosis of axSpA and must be prescribed upadacitinib before joining the study. Key factors for eligibility include not having used any similar medications (called Janus kinase inhibitors) in the past and being able to take upadacitinib according to local guidelines. Participants can expect regular check-ups to monitor their health and any side effects from the treatment, along with completing questionnaires about their pain and quality of life. This trial is a great opportunity for those struggling with axSpA to potentially find relief while contributing to important research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical diagnosis of axSpA upon physician's judgement.
- • Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
- • Upadacitinib prescribed in accordance with the local label.
- Exclusion Criteria:
- • Prior exposure to any Janus kinase (JAK) inhibitor (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib).
- • Participants with primary fibromyalgia (upon physician´s judgement)
- • Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days or five half-lives of the drug (whichever is longer) prior to the first dose of study drug or is currently enrolled in another clinical study.
- • Participants who cannot be treated with upadacitinib according to the applicable local label.
About Abbvie
AbbVie is a global biopharmaceutical company dedicated to developing innovative therapies that address complex health challenges. Founded in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on key therapeutic areas, including immunology, oncology, neuroscience, and virology. The company is committed to advancing scientific research and delivering groundbreaking treatments that enhance patient outcomes and quality of life. With a robust pipeline and a strong emphasis on collaboration, AbbVie strives to transform the future of medicine through its commitment to clinical excellence and patient-centered approaches.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ulm, Baden Wuerttemberg, Germany
Munich, Bayern, Germany
Potsdam, Brandenburg, Germany
Gießen, Hessen, Germany
Bruchhausen Vilsen, Niedersachsen, Germany
Herne, Nordrhein Westfalen, Germany
Herne, Nordrhein Westfalen, Germany
Altenburg, , Germany
Amberg, , Germany
Augsburg, , Germany
Bad Bertrich, , Germany
Bad Pyrmont, , Germany
Baden Baden, , Germany
Bayreuth, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Berlin, , Germany
Braunschweig, , Germany
Burghausen, , Germany
Chemnitz, , Germany
Coburg, , Germany
Cologne, , Germany
Cologne, , Germany
Demmin, , Germany
Dresden, , Germany
Düren, , Germany
Ehringshausen, , Germany
Erfurt, , Germany
Freiberg, , Germany
Gifhorn, , Germany
Goettingen, , Germany
Halle, , Germany
Hamburg, , Germany
Hanover, , Germany
Heidelberg, , Germany
Homburg, , Germany
Hoppegarten, , Germany
Juelich, , Germany
Kaiserslautern, , Germany
Langenau, , Germany
Leipzig, , Germany
Leipzig, , Germany
Magdeburg, , Germany
Mansfeld / Großörner, , Germany
Marktredwitz, , Germany
Meerbusch, , Germany
Munich, , Germany
Naumburg (Saale), , Germany
Neubrandenburg, , Germany
Nienburg, , Germany
Planegg, , Germany
Plauen, , Germany
Potsdam, , Germany
Püttlingen, , Germany
Ratingen, , Germany
Schwerin, , Germany
Seesen, , Germany
Stadtoldendorf, , Germany
Straubing, , Germany
Stuttgart, , Germany
Stuttgart, , Germany
Trier, , Germany
Tuebingen, , Germany
Ulm, , Germany
Wuppertal, , Germany
Wuppertal, , Germany
Zeven, , Germany
Zwickau, , Germany
Baden Baden, , Germany
Burglengenfeld, , Germany
Hohen Neuendorf, , Germany
Rendsburg, , Germany
Wuppertal, , Germany
Ludwigshafen, , Germany
Erfurt, , Germany
Püttlingen, Saarland, Germany
Bad Nauheim, , Germany
Daun, , Germany
Hamburg, , Germany
Hannover, , Germany
Planegg, , Germany
Waren (Müritz), , Germany
Tuebingen, Baden Wuerttemberg, Germany
Hoppegarten, Brandenburg, Germany
Potsdam, Brandenburg, Germany
Homburg, Saarland, Germany
Hannover, , Germany
Herne, , Germany
Trier, , Germany
Weimar, Thueringen, Germany
Berlin, , Germany
Brunswick, , Germany
Baden Baden, Saarland, Germany
Chemnitz, Saarland, Germany
Cologne, Saarland, Germany
Erfurt, Saarland, Germany
Halle, Saarland, Germany
Hannover, Saarland, Germany
Heidelberg, Saarland, Germany
Herne, Saarland, Germany
Kaiserslautern, Saarland, Germany
Leipzig, Saarland, Germany
Leipzig, Saarland, Germany
Magdeburg, Saarland, Germany
Rendsburg, Saarland, Germany
Stuttgart, Saarland, Germany
Trier, Saarland, Germany
Baden Baden, Baden Wuerttemberg, Germany
Heidelberg, Baden Wuerttemberg, Germany
Stuttgart, Baden Wuerttemberg, Germany
Hannover, Niedersachsen, Germany
Cologne, Nordrhein Westfalen, Germany
Kaiserslautern, Rheinland Pfalz, Germany
Trier, Rheinland Pfalz, Germany
Halle, Sachsen Anhalt, Germany
Magdeburg, Sachsen Anhalt, Germany
Chemnitz, Sachsen, Germany
Leipzig, Sachsen, Germany
Leipzig, Sachsen, Germany
Rendsburg, Schleswig Holstein, Germany
Erfurt, Thueringen, Germany
Hanover, Niedersachsen, Germany
Kassel, Niedersachsen, Germany
Patients applied
Trial Officials
ABBVIE INC.
Study Director
AbbVie
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials